Charles River Laboratories (NYSE: CRL)

Charles River Laboratories International, Inc., together with its subsidiaries, provides research models and associated services, and outsourced preclinical services to accelerate the drug discovery and development process. It operates in two segments, Research Models and Services (RMS), and Preclinical Services (PCS). The RMS segment is involved in the production and sale of research model strains, principally genetically and microbiologically defined purpose-bred rats and mice for use by researchers. The PCS segment provides preclinical services, including both in vivo and in vitro studies, supportive laboratory services, and strategic preclinical consulting and program management to support product development.
To review Charles' stock, please take a look at the 1-year chart of CRL (Charles River Laboratories International, Inc.) below with my added notations:
Since December of last year CRL has grinded its way higher. Over the last 7 months though, the stock has formed a key level of $46 (blue) and an area of resistance at $48 (red). That resistance is also a 52-week high resistance. After a brief, fake, breakdown last month, the stock appears to be headed back up towards its $48 resistance.

The Tale of the Tape: CRL has a $46 level of support and a $48 resistance to watch. A long trade could be made on either a pullback down to $46, or on a break above $48. A break below $46 would be a great time to consider a short trade.
Please share this article